secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001104659-26-057226
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Structure Therapeutics Amends Sales Agreement to Raise ATM Capacity to $400M and Reports Q1 2026 Financials
--------------------------------------------------------------------------------

- Amended and restated Sales Agreement with Leerink Partners and Cantor Fitzgerald to remove aggregate offering limit and filed prospectus supplement increasing ATM by $150M to $400M.
- Aleniglipron Phase 2 ACCESS II achieved placebo-adjusted weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks.
- Cash, cash equivalents and short-term investments totaled $1.5 billion as of March 31, 2026; received $100M upfront license fee in Q1.
- FDA provided positive end-of-Phase 2 feedback; Phase 3 program for aleniglipron expected to initiate in Q3 2026.
- Net loss for Q1 2026 was $76.0 million, including $11.6 million non-cash share-based compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465926057226/0001104659-26-057226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465926057226/tm2613721d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-057226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer